Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma

Yuko Nomura, Shiro Yoshida, Kennosuke Karube, Morishige Takeshita, Shinichi Hirose, Shigeo Nakamura, Tadashi Yoshino, Masahiro Kikuchi, Koichi Ohshima

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Burkitt's lymphoma and atypical Burkitt/Burkitt-like lymphoma (BL/BLL) are considered highly aggressive B-cell lymphomas with a rapid proliferative rate and high rate of apoptosis. The aim of the present study was to confirm whether apoptotic and cell proliferative factors affect BL/BLL clinical outcomes. We retrospectively analyzed the relationship between the clinical and immunophenotypic features of 43 BL/ BLL patients by immunohistochemical staining for bcl-2 and double staining for Ki-67 plus caspase-3. In double staining experiments, all patients were divided into high and low groups for the expression of caspase-3, Ki-67, and both Ki-67 and caspase-3, by using the medians of their percentages as limits. The 43 BL/BLL patients were divided into high caspase-3 (n = 19) and low caspase-3 (n = 24) groups. There was a significant difference in the overall survival between the high (77%) and low caspase-3 (33%) groups; the survival rate of patients in the low caspase-3 group who received aggressive short-term chemotherapy (58%) was significantly better than that of patients who received cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) therapy (17%). All patients positive for bcl-2 were in the low caspase-3 group (high caspase-3 group, 0% low caspase-3 group, 42%). The overall survival tended to be better in the high caspase-3 and bcl-2-negative group (76%) than in the low caspase-3 and bcl-2-negative (50%) group. In addition, the low caspase-3 and bcl-2-positive group tended to show the worst prognosis (16%). We suggest that caspase-3 may function as an indicator of the prognosis of BL/BLL. Furthermore, intensive short-term chemotherapeutic regimens may improve the prognosis of the patients in the low caspase-3 group.

Original languageEnglish
Pages (from-to)1564-1569
Number of pages6
JournalCancer Science
Volume99
Issue number8
DOIs
Publication statusPublished - 2008

Fingerprint

Burkitt Lymphoma
Caspase 3
Staining and Labeling
Survival
Vincristine
B-Cell Lymphoma
Prednisolone
Doxorubicin
Cyclophosphamide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nomura, Y., Yoshida, S., Karube, K., Takeshita, M., Hirose, S., Nakamura, S., ... Ohshima, K. (2008). Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. Cancer Science, 99(8), 1564-1569. https://doi.org/10.1111/j.1349-7006.2008.00851.x

Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. / Nomura, Yuko; Yoshida, Shiro; Karube, Kennosuke; Takeshita, Morishige; Hirose, Shinichi; Nakamura, Shigeo; Yoshino, Tadashi; Kikuchi, Masahiro; Ohshima, Koichi.

In: Cancer Science, Vol. 99, No. 8, 2008, p. 1564-1569.

Research output: Contribution to journalArticle

Nomura, Y, Yoshida, S, Karube, K, Takeshita, M, Hirose, S, Nakamura, S, Yoshino, T, Kikuchi, M & Ohshima, K 2008, 'Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma', Cancer Science, vol. 99, no. 8, pp. 1564-1569. https://doi.org/10.1111/j.1349-7006.2008.00851.x
Nomura, Yuko ; Yoshida, Shiro ; Karube, Kennosuke ; Takeshita, Morishige ; Hirose, Shinichi ; Nakamura, Shigeo ; Yoshino, Tadashi ; Kikuchi, Masahiro ; Ohshima, Koichi. / Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. In: Cancer Science. 2008 ; Vol. 99, No. 8. pp. 1564-1569.
@article{58313bf786d543b38ba1b7eb6417aa55,
title = "Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma",
abstract = "Burkitt's lymphoma and atypical Burkitt/Burkitt-like lymphoma (BL/BLL) are considered highly aggressive B-cell lymphomas with a rapid proliferative rate and high rate of apoptosis. The aim of the present study was to confirm whether apoptotic and cell proliferative factors affect BL/BLL clinical outcomes. We retrospectively analyzed the relationship between the clinical and immunophenotypic features of 43 BL/ BLL patients by immunohistochemical staining for bcl-2 and double staining for Ki-67 plus caspase-3. In double staining experiments, all patients were divided into high and low groups for the expression of caspase-3, Ki-67, and both Ki-67 and caspase-3, by using the medians of their percentages as limits. The 43 BL/BLL patients were divided into high caspase-3 (n = 19) and low caspase-3 (n = 24) groups. There was a significant difference in the overall survival between the high (77{\%}) and low caspase-3 (33{\%}) groups; the survival rate of patients in the low caspase-3 group who received aggressive short-term chemotherapy (58{\%}) was significantly better than that of patients who received cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) therapy (17{\%}). All patients positive for bcl-2 were in the low caspase-3 group (high caspase-3 group, 0{\%} low caspase-3 group, 42{\%}). The overall survival tended to be better in the high caspase-3 and bcl-2-negative group (76{\%}) than in the low caspase-3 and bcl-2-negative (50{\%}) group. In addition, the low caspase-3 and bcl-2-positive group tended to show the worst prognosis (16{\%}). We suggest that caspase-3 may function as an indicator of the prognosis of BL/BLL. Furthermore, intensive short-term chemotherapeutic regimens may improve the prognosis of the patients in the low caspase-3 group.",
author = "Yuko Nomura and Shiro Yoshida and Kennosuke Karube and Morishige Takeshita and Shinichi Hirose and Shigeo Nakamura and Tadashi Yoshino and Masahiro Kikuchi and Koichi Ohshima",
year = "2008",
doi = "10.1111/j.1349-7006.2008.00851.x",
language = "English",
volume = "99",
pages = "1564--1569",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma

AU - Nomura, Yuko

AU - Yoshida, Shiro

AU - Karube, Kennosuke

AU - Takeshita, Morishige

AU - Hirose, Shinichi

AU - Nakamura, Shigeo

AU - Yoshino, Tadashi

AU - Kikuchi, Masahiro

AU - Ohshima, Koichi

PY - 2008

Y1 - 2008

N2 - Burkitt's lymphoma and atypical Burkitt/Burkitt-like lymphoma (BL/BLL) are considered highly aggressive B-cell lymphomas with a rapid proliferative rate and high rate of apoptosis. The aim of the present study was to confirm whether apoptotic and cell proliferative factors affect BL/BLL clinical outcomes. We retrospectively analyzed the relationship between the clinical and immunophenotypic features of 43 BL/ BLL patients by immunohistochemical staining for bcl-2 and double staining for Ki-67 plus caspase-3. In double staining experiments, all patients were divided into high and low groups for the expression of caspase-3, Ki-67, and both Ki-67 and caspase-3, by using the medians of their percentages as limits. The 43 BL/BLL patients were divided into high caspase-3 (n = 19) and low caspase-3 (n = 24) groups. There was a significant difference in the overall survival between the high (77%) and low caspase-3 (33%) groups; the survival rate of patients in the low caspase-3 group who received aggressive short-term chemotherapy (58%) was significantly better than that of patients who received cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) therapy (17%). All patients positive for bcl-2 were in the low caspase-3 group (high caspase-3 group, 0% low caspase-3 group, 42%). The overall survival tended to be better in the high caspase-3 and bcl-2-negative group (76%) than in the low caspase-3 and bcl-2-negative (50%) group. In addition, the low caspase-3 and bcl-2-positive group tended to show the worst prognosis (16%). We suggest that caspase-3 may function as an indicator of the prognosis of BL/BLL. Furthermore, intensive short-term chemotherapeutic regimens may improve the prognosis of the patients in the low caspase-3 group.

AB - Burkitt's lymphoma and atypical Burkitt/Burkitt-like lymphoma (BL/BLL) are considered highly aggressive B-cell lymphomas with a rapid proliferative rate and high rate of apoptosis. The aim of the present study was to confirm whether apoptotic and cell proliferative factors affect BL/BLL clinical outcomes. We retrospectively analyzed the relationship between the clinical and immunophenotypic features of 43 BL/ BLL patients by immunohistochemical staining for bcl-2 and double staining for Ki-67 plus caspase-3. In double staining experiments, all patients were divided into high and low groups for the expression of caspase-3, Ki-67, and both Ki-67 and caspase-3, by using the medians of their percentages as limits. The 43 BL/BLL patients were divided into high caspase-3 (n = 19) and low caspase-3 (n = 24) groups. There was a significant difference in the overall survival between the high (77%) and low caspase-3 (33%) groups; the survival rate of patients in the low caspase-3 group who received aggressive short-term chemotherapy (58%) was significantly better than that of patients who received cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) therapy (17%). All patients positive for bcl-2 were in the low caspase-3 group (high caspase-3 group, 0% low caspase-3 group, 42%). The overall survival tended to be better in the high caspase-3 and bcl-2-negative group (76%) than in the low caspase-3 and bcl-2-negative (50%) group. In addition, the low caspase-3 and bcl-2-positive group tended to show the worst prognosis (16%). We suggest that caspase-3 may function as an indicator of the prognosis of BL/BLL. Furthermore, intensive short-term chemotherapeutic regimens may improve the prognosis of the patients in the low caspase-3 group.

UR - http://www.scopus.com/inward/record.url?scp=49749116792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749116792&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2008.00851.x

DO - 10.1111/j.1349-7006.2008.00851.x

M3 - Article

C2 - 18754867

AN - SCOPUS:49749116792

VL - 99

SP - 1564

EP - 1569

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -